



Zurich, June 12, 2007

Dear BioDevice Partnering Participant:

Welcome to Zurich and to BioDevice Partnering 2007!

Following the success of the inaugural BioDevice Partnering 2006 in Edinburgh, we are pleased to inform you that we are establishing this conference as an annual international event.

The overwhelming positive feedback we received from delegates last year about BioDevice Partnering 2006 confirmed that the medical device industry has a great need for a dedicated professional partnering forum to facilitate connections among the high-tech end of the medical device industry and other sectors such as biotech/pharma, regenerative medicine and biomaterials.

We recognize that there are many exciting innovations in medical technology beyond "convergence", and have therefore expanded this year's BioDevice Partnering event to be a business development platform for a broader range of novel biomedical technologies.

We encourage you to take full advantage of the capabilities inherent to our partnering system to identify and engage with many potential strategic partners attending the conference. In addition, we hope that you can participate in and benefit from a full complement of corporate presentations, informative high level panels and conference networking events.

EBD Group and Eucomed extend their thanks to the Host Sponsor SwissMedtech, the Regional Host Committee and our numerous other sponsors for their generous support and assistance in making BioDevice Partnering 2007 possible.

If you have any questions or need assistance during the course of the conference, our staff will be available to assist you. We wish you a very successful conference and look forward to seeing you again next year at BioDevice Partnering 2008!

Sincerely,

Carola Schropp
Managing Director
EBD Group



Maurice Wagner
Director General
Eucomed



Host Sponsor

SwissMedtech

Regional Host Committee

BB MEDTECH

Credit Suisse

ETH Zurich

Greater Zurich Area

SWX Swiss Exchange

Major Sponsors

Abingworth
Management Ltd

Epstein Becker & Green

FUJIFILM Life Science

Mayer, Brown,
Rowe & Maw

Organogenesis

Smith & Nephew


Scheduled Events



Tuesday, June 12, 2007

WHEN	WHAT	WHERE
07:00	Registration opens	Level 0, Main Entrance
07:00	Continental Breakfast	Level 0, Foyer Auditorium
09:00–10:30	Welcome & Opening Plenary Session	
	Welcome and Opening	Level 0, Auditorium
	<ul style="list-style-type: none"> • Carola Schropp, Managing Director, EBD Group • Dr. Maurice Wagner, General Director, Eucomed • SwissMedtech Representative 	
	Opportunities and Challenges for New Medical Technologies	Level 0, Auditorium
	MODERATOR: David Cassak, Managing Partner, Windhover Information Inc.	
	PANELIST,	
	<ul style="list-style-type: none"> • Dr. Erik Baas, Director, Medicine and Technology, International, Medtronic • Tom Bailey, CFO, Angiotech Pharmaceuticals, Inc. • Tim Haines, Partner, Abingworth Management Ltd • Crispin Simon, CEO, Biocompatibles International Plc 	
10:30–11:00	Coffee Break	Level 0, Foyer Auditorium
10:30–18:00	Partnering	
	One-on-One Partnering Meetings	Level 0, Booths 100–143
	Sponsor Private Meeting Rooms	Level 3 Room B: SwissMedtech Room C: FUJIFILM Life Science
11:00–13:00	Company Presentations	
	Group 1: Orthopedics	Level 1, Haus Newton, Room 1008
	Group 2: Drug Delivery	Level 1, Haus Newton, Room 1011
13:00–14:30	Lunch	NOVOTEL, Ground Level Exit via the main entrance and cross the street. The Novotel is to your right.
14:30–15:45	Company Presentations	
	Group 1: Regenerative Medicine	Level 1, Haus Newton, Room 1008
	Group 2: Cardiovascular	Level 1, Haus Newton, Room 1011
15:45–16:45	Technology Transfer Track	
	Technology Transfer	Level 1, Haus Newton, Room 1008

Tuesday, June 12, 2007

WHEN	WHAT	WHERE
16:45–17:00	Coffee Break	Level 0, Foyer Auditorium
17:00–18:00	Plenary Session	
	The Changing World of Orthopedics: Looking into the Future	Level 0, Auditorium
	MODERATOR:	
	<ul style="list-style-type: none">• Dr. Olivier Litzka, Partner Life Sciences, Edmond de Rothschild Investment Partners	
	PANELISTS:	
	<ul style="list-style-type: none">• Gil Beyen, CEO, TiGenix NV• Bruce de la Grange, Director of Corporate Business Development, Plus Orthopedics AG• Dr. Peter Heeckt, CMO, Smith & Nephew Orthopaedics• Anthony Viscogliosi, Chairman & CEO, Small Bone Innovations, Inc.	
18:15–18:45	Shuttle buses leave to evening venue	Main Entrance Technopark
19:00	Networking Dinner Event	Lake Side Restaurant (www.lake-side.ch) Bellerivestrasse 170 8008 Zurich
	Sponsored & hosted by:	
	SWISS  MEDTECH	20 minutes by taxi
21:00–22:00	Shuttle buses leave every 15 minutes from Evening Event to ALL Conference Hotels.	

Wednesday, June 13, 2007

WHEN	WHAT	WHERE
07:30	Registration opens	Level 0, Main Entrance
07:30	Continental Breakfast	Level 0, Foyer Auditorium
08:30–16:30	<i>Partnering</i>	
	One-on-One Partnering Meetings	Level 0, Booths 100–143
	Sponsor Private Meeting Rooms	Level 3 Room B: SwissMedtech Room C: FUJIFILM Life Science
08:30–09:30	<i>Plenary Session</i>	
	Biomaterials and Polymers: Transforming the Industry	Level 0, Auditorium
	MODERATOR:	
	<ul style="list-style-type: none">• Dr. Don Long, Executive Editor, Medical Device Daily, AHC Media	
	PANELISTS:	
	<ul style="list-style-type: none">• Dr. John Devine, Senior Product Development Manager, Invibio Ltd.• Dr. Murray Height, Chief Technology Officer, HeiQ Materials AG• Dr. Darren Obrigkeit, Licensing & Venturing Manager, DSM Biomedical• Dr. Alessandra Pavesio, Director, R&D Dept., Fidia Advanced Biopolymers Srl	
09:30–10:00	Coffee Break	Level 0, Foyer Auditorium
10:00–11:00	<i>Company Presentations</i>	
	Group 1: Biomaterials/Polymers	Level 1, Haus Newton, Room 1008
	Group 2: Diagnostics/Imaging	Level 1, Haus Newton, Room 1011
11:00–11:30	Coffee Break	Level 0, Foyer Auditorium
11:30–12:30	<i>Plenary Session</i>	
	Creative Regulatory Pathways to Commercialization	Level 0, Auditorium
	MODERATOR:	
	<ul style="list-style-type: none">• Diana Romza-Kutz, Member of the Firm, Health Care and Life Sciences Practice, Epstein Becker & Green P.C.	
	PANELISTS:	
	<ul style="list-style-type: none">• Patrick Bilbo, VP, Regulatory & Clinical Affairs, Organogenesis Inc.• Michel Lussier, Chairman, Cardio³• Eliane Schutte, Senior Partner, Signifix BV• Dr. Maurice Wagner, General Director, Eucomed	

Wednesday, June 13, 2007

WHEN	WHAT	WHERE
12:30–14:00	Lunch	NOVOTEL, Ground Level Exit via the main entrance and cross the street. The Novotel is to your right.
14:00–15:00	Company Presentations	
	Group 1: Biomaterials/Polymers	Level 1, Haus Newton, Room 1008
	Group 2: Diagnostics/Imaging	Level 1, Haus Newton, Room 1011
15:00–15:30	Coffee Break	Level 0, Foyer Auditorium
15:30–16:30	Plenary Session	
	The Medtech Wave: When did It Start, Why and How Best to Take Advantage of It?	Level 0, Auditorium
	MODERATOR:	
	<ul style="list-style-type: none">David Cassak, Managing Partner, Windhover Information Inc.	
	PANELISTS:	
	<ul style="list-style-type: none">Dr. Yvonne Gunsch-Wegmann, VP, Head of Issuer & Investor Relations, SWX Swiss ExchangeDr. Christian Lach, Member of the Healthcare Team, BB MedtechDr. Ruediger Herrmann, Partner, Mayer Brown Rowe & Maw LLPGiles Keating, Head of Global Research, Credit Suisse Private Banking	
16:30	Closing Reception	Level 0, Foyer Auditorium

Company Presentations Schedule

Tuesday, June 12, 2007

LEVEL 1, ROOM 1008		LEVEL 1, ROOM 1011	
11:00	OrthoMimetics Ltd	Drug Delivery	EnzySurge
11:15	Paradigm Spine LLC		Inovio Biomedical Corporation
11:30	Xylos Corporation		BioCure Inc
11:45	Altavance		Kurve Technology, Inc.
12:00	Smith & Nephew plc		Medical Device Works NV/ SA
12:15	Raymedica, LLC		DSM Biomedical
12:30	Small Bone Innovations, Inc.		CIS Pharma
12:45	Praxim		BioCardia
Regenerative Medicine 14:30 Organogenesis Inc. 14:45 Biocompatibles International plc 15:00 Intercytex Group plc 15:15 TiGenix NV 15:30 Cardio ³		Cardiovascular	Nerites Corporation
			Micromuscle AB
			Angiotech
			Bioring SA
			TBA
Technology Transfer 15:45 NHS Innovations London 16:00 ETH Zürich 16:15 University of Geneva/Unitec 16:30 De Montfort University			

Wednesday, June 13, 2007

LEVEL 1, ROOM 1008		LEVEL 1, ROOM 1011	
10:00	HeiQ Materials AG	Diagnostics/ Imaging	Solianis Monitoring AG
10:15	IMI Intelligent Medical Implants AG		Advanced Medical Diagnostics SA.
10:30	Kuros Biosurgery AG		Calypso Medical
10:45	FUJIFILM Life Science		Orla Protein Technologies Ltd
Biomaterials/ Polymers 14:00 PolyMedix, Inc. 14:15 Tethis S.r.l. 14:30 Novathera Ltd 14:45 Devro Plc		Diagnostics/ Imaging	Perceptronix Medical Inc.
			ART Advanced Research Technologies Inc.
			Echosens
			Oxford Biosensors


Company Presentations

Alphabetical Listing

COMPANY	CATEGORY	DATE	TIME	ROOM, LEVEL 1
Advanced Medical Diagnostics SA.	Diagnostics/Imaging	Wednesday	10:15 am	1011
Altavance	Orthopedics	Tuesday	11:45 am	1008
Angiotech	Cardiovascular	Tuesday	3:00 pm	1011
ART Advanced Research Technologies Inc.	Diagnostics/Imaging	Wednesday	2:15 pm	1011
BioCardia	Drug Delivery	Tuesday	12:45 pm	1011
Biocompatibles International plc	Regenerative Medicine	Tuesday	2:45 pm	1008
BioCure Inc	Drug Delivery	Tuesday	11:30 am	1011
Bioring SA	Cardiovascular	Tuesday	3:15 pm	1011
Calypso Medical	Diagnostics/Imaging	Wednesday	10:30 am	1011
Cardio ³	Regenerative Medicine	Tuesday	3:30 pm	1008
CIS Pharma	Drug Delivery	Tuesday	12:30 pm	1011
De Montfort University	Tech Transfer	Tuesday	4:30 pm	1008
Devro Plc	Biomaterials/Polymers	Wednesday	2:45 pm	1008
DSM Biomedical	Drug Delivery	Tuesday	12:15 pm	1011
Echosens	Diagnostics/Imaging	Wednesday	2:30 pm	1011
EnzySurge	Drug Delivery	Tuesday	11:00 am	1011
ETH Zürich	Tech Transfer	Tuesday	4:00 pm	1008
FUJIFILM Life Science	Biomaterials/Polymers	Wednesday	10:45 am	1008
HeiQ Materials AG	Biomaterials/Polymers	Wednesday	10:00 am	1008
IMI Intelligent Medical Implants AG	Biomaterials/Polymers	Wednesday	10:15 am	1008
Inovio Biomedical Corporation	Drug Delivery	Tuesday	11:15 pm	1011
Intercytex Group plc	Regenerative Medicine	Tuesday	3:00 pm	1008
Kuros Biosurgery AG	Biomaterials/Polymers	Wednesday	10:30 am	1008
Kurve Technology, Inc.	Drug Delivery	Tuesday	11:45 pm	1011
Medical Device Works NV/ SA	Drug Delivery	Tuesday	12:00 pm	1011
Micromuscle AB	Cardiovascular	Tuesday	2:45 pm	1011
Nerites Corporation	Cardiovascular	Tuesday	2:30 pm	1011
NHS Innovations London	Tech Transfer	Tuesday	3:45 pm	1008
Novathera Ltd	Biomaterials/Polymers	Wednesday	2:30 pm	1008
Organogenesis Inc.	Regenerative Medicine	Tuesday	2:30 pm	1008
Orla Protein Technologies Ltd	Diagnostics/Imaging	Wednesday	10:45 am	1011
OrthoMimetics Ltd	Orthopedics	Tuesday	11:00 am	1008
Oxford Biosensors	Diagnostics/Imaging	Wednesday	2:45 pm	1011
Paradigm Spine LLC	Orthopedics	Tuesday	11:15 am	1008
Perceptronix Medical Inc.	Diagnostics/Imaging	Wednesday	2:00 am	1011
PolyMedix, Inc.	Biomaterials/Polymers	Wednesday	2:00 pm	1008
Praxim	Orthopedics	Tuesday	12:45 pm	1008
Raymedica, LLC	Orthopedics	Tuesday	12:15 pm	1008
Small Bone Innovations, Inc.	Orthopedics	Tuesday	12:30 pm	1008
Smith & Nephew plc	Orthopedics	Tuesday	12:00 pm	1008
Solianis Monitoring AG	Diagnostics/Imaging	Wednesday	10:00 am	1011
Tethis S.r.l.	Biomaterials/Polymers	Wednesday	2:15 pm	1008
TiGenix NV	Regenerative Medicine	Tuesday	3:15 pm	1008
University of Geneva/Unitec	Tech Transfer	Tuesday	4:15 pm	1008
Xylos Corporation	Orthopedics	Tuesday	11:30 am	1008

Exhibit Area

Foyer Auditorium, Level 0



Speaker Biographies

Dr. Erik Baas holds the position of Director, Medicine and Technology, International at Medtronic where he is responsible for sourcing of technologies and product opportunities that will have a significant impact on Medtronic, originating outside the USA. In close partnership with Medtronic corporate and business units, he develops close collaborations with medical key opinion leaders, VC firms and universities, and with Medtronic's diverse customer base.

Erik has worked within the biomedical, pharmaceutical, bioscience and IT fields where he has held roles in project management, business planning, and market development. His previous appointments have included the Netherlands Cancer Institute, DSM / Genencor International, Arthur D. Little, and several VC funded start-ups.

Erik holds an MS in Biochemistry and Molecular Biology from the University of Amsterdam, a PhD in Biochemistry from the Free University of Amsterdam and an MBA from IMD in Lausanne.

Tom Bailey is Angiotech's Chief Financial Officer and is responsible for overseeing the company's overall financial activities. In addition, he manages Angiotech's corporate growth initiatives such as acquisitions, corporate alliances and partnerships. Prior to joining Angiotech in 2003, he worked for over a decade as an investment banker, most recently as leader of the biotechnology practice group at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette, where he advised on over 50 completed transactions for biotechnology, pharmaceutical and medical device companies, including mergers, acquisitions, strategic alliances and a wide range of equity, equity-linked and debt financings, and worked with the firms' merchant banking and venture capital groups to identify and complete significant investments in life sciences companies.

Mr. Bailey received his AB in Economics from Harvard University in 1990 and his MBA from Harvard Business School in 1995.

Gil Beyen is Co-founder and CEO of TiGenix. Before founding TiGenix, he worked as a management consultant at Arthur D. Little (ADL) in Brussels, where he was a Partner responsible for their Healthcare and Biotechnology Practice. As a consultant he has assisted a broad range of companies in the biomedical and biotech industries through different stages of their growth. Before that he worked as a Project Engineer in the biotechnology R&D group of Artois Engineering.

Mr. Beyen is Member of the Board of FlandersBio VZW, and Commissioner (regeringscommissaris) for the Flemish government on the board of the Flemish Institute of Biotechnology (VIB). He holds an MSc in Bioengineering from the University of Leuven (Belgium) in 1984 and obtained an MBA from the University of Chicago (US) in 1990.

Patrick Bilbo is Vice President, Regulatory & Clinical Affairs at Organogenesis Inc. He has over 19 years experience in the medical products industry, with a broad range of expertise in the development and commercialization of device and biotech products including responsibility for clinical research, regulatory affairs and product development. In his current position he directs the preclinical, clinical and regulatory programs at Organogenesis, a leading tissue regeneration company with headquarters in the Boston area. Previously he held management and research positions at Cytoc Corporation and Stryker Corporation. Prior to his career in industry, Mr. Bilbo gained four years of research experience in the Cell Biology Department at Harvard Medical School.

Mr. Bilbo has an MBA degree from the Boston University Graduate School of Management, Masters degrees in Cell Biology and Technology Strategy/Policy from the Boston University Graduate School of Arts & Sciences, and a B.S. degree in Biology from Syracuse University.

David Cassak is a Managing Partner of Windhover Information Inc., a Norwalk, CT-based health care business information company. In 1989, Mr. Cassak, along with his partner Roger Longman, led a buyout of the publications business of The Wilkerson Group, forming Windhover Information Inc. In addition to IN VIVO, Windhover publishes START-UP, Medtech Insight, and The RPM Report. The company also offers an extensive database of health care M&A, financing, and strategic alliance transactions, Strategic Intelligence Systems, and a broad-based conference business covering both medical devices and biopharmaceuticals.

Before launching Windhover, Mr. Cassak was with The Wilkerson Group, a health care consulting company, as an editor of IN VIVO. Previously, he was with Cassak Publications Inc., a family-run business that published trade journals for the hospital and alternate site distribution industries.

Mr. Cassak earned a BA from Drew University and did graduate work at Columbia and Princeton, earning an MA, with honors from the former. Mr. Cassak writes extensively about the medical device and hospital supply industries and is a frequent speaker before various companies and industry trade groups.

Dr. John Devine holds the position of Senior Product Development Manager with Invibio Biomaterial Solutions. This role involves developing and creating new materials for specific application needs in applications areas such

Speaker Biographies

as spine, general orthopaedics and dental, in addition to generating application specific data to accelerate pace and acceptance of new materials in conservative application areas.

Dr. Devine has a background in chemistry and a doctorate in the area of structure/property relationships in polymeric materials, funded by the Defence Evaluation Research Agency. He joined Victrex in 1999 and has worked on the development of novel materials for the semi-conductor and fuel cell membrane market in addition to optimisation of small, medium and large scale polyketone manufacture, prior to joining Invibio in 2003.

Operating closely at the material/device interface, Dr. Devine provides insight into the demands and challenges in introducing new biomaterials within the implantable devices market, in addition to a broad knowledge of current biomaterial offerings and challenges. Dr. Devine is a named inventor on a number of patented inventions and has contributed to presentations at shows such as Spinal Arthroplasty Society, British Orthopaedic Society and Society for Biomaterials in addition to authoring peer reviewed articles.

Working with Invibio, Dr. Devine has helped introduce a range of PEEK-OPTIMA® materials to the market and has a current interest in the potential of these materials as bearing components in spinal arthroplasty, hip resurfacing and in small joints and is currently completing a Masters degree in Process Management and Technology.

Bruce de la Grange is Director of Corporate Business Development of Plus Orthopedics, AG, a post he has held since April 2002. In this capacity, he has overall responsibility for the development of group strategy and the evaluation of new business opportunities. He also heads up the Regenerative medicine task force, an interdisciplinary matrix group within the Plus Orthopedics structure, which is particularly charged with the identification and development of business activities in the field of orthobiologics.

Since 2003, Mr. de la GRANGE has had primary responsibility for Lifetek, LLC of Gainesville, Florida and Biograft de Mexico, SA de CV of Mexico City, Mexico, subsidiaries of the Plus Orthopedics group which are engaged in the production of Allograft Bone Graft substitutes. His past responsibilities at Plus Orthopedics include responsibility for the Chinese and Japanese subsidiaries of the Plus Orthopedics Group.

He earned his AB, with Honors in Economics (Honors thesis subject: Small Business Investment Companies), and His MBA at the Wharton School of the University of Pennsylvania, Philadelphia, Pennsylvania.

Mr. de la GRANGE began his career in Orthopedics with Zimmer, Europe, where he was Managing Director, in 1976. Prior to joining Plus Orthopedics, he was Managing Director of DePuy France, Spain, Portugal and Belgium from 1990 to 2001.

In the years between Zimmer and DePuy, Mr. de la GRANGE worked as an independent consultant (the World Food Program of the United Nations was one of his clients) and from 1983 to 1987, he was Vice-President of the American University in Paris and then Managing Director of the MBA Institute in Paris.

Dr. Yvonne Gunsch-Wegmann is Vice President and Head of Issuer & Investor Relations at SWX Swiss Exchange. She has worked for the SWX Swiss Exchange since November 2004. She is in charge of the Issuer and Investor Relations department of the SWX Swiss Exchange and its subsidiary virt-x, the pan-European blue chip exchange in London.

Before joining the SWX Swiss Exchange, Dr. Gunsch-Wegmann was in charge of Business Development at Switzerland's leading private clinic group, Hirslanden. She previously headed up a major project, promoting health in the private sector, for Prof. Dr. Felix Gutzwiller, Director of the Institute of Social and Preventive Medicine at the University of Zurich.

Yvonne Gunsch-Wegmann is a doctor of medicine and has many years of clinical and scientific experience in the medical field. She has studied and worked in the USA and Italy, gained her doctorate from the University of Zurich and also holds an Executive MBA from the University of St. Gallen.

Tim Haines is a Partner at Abingworth Management Ltd. He has more than 23 years of international management experience in the life sciences industry. Before joining Abingworth in September 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. During his time at Astex, the company accessed more than £50 million in venture capital and closed over \$1b in deal value potential with pharmaceutical companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe.

Tim has a BSc from Exeter University and an MBA from INSEAD. Current and past portfolio board positions include Astex Therapeutics, Fovea SA, X-Counter AB (AIM-listed), Powdermed (acquired by Pfizer), Akubio and IMI AG.

Speaker Biographies

Dr. Peter Heeckt is the Chief Medical Officer at Smith & Nephew, Inc., in Memphis, Tennessee. In this role he is primarily responsible for Patient Safety and Advocacy as well as Clinical Affairs. Dr. Heeckt has previously served as the Medical Director of Fresenius ProServe for Fresenius AG in Oberursel, Germany, as the Director of Blasticon Biotechnological Research GmbH in Kiel, Germany, as the Director of the Surgical Academy, Maquet AG in Rastatt, Germany, and as Medical Director of Orto Maquet GmbH & Co. KG in Rastatt, Germany.

He earned his MD at the University of Munich Medical School, and completed a fellowship at the Klinikum Bogenhausen Department of Plastic, Reconstructive, Hand and Burn Surgery in Munich, Germany. Dr. Heeckt completed his residency at the University of Ulm Department of Surgery in Ulm, Germany, and a research fellowship at the University of Pittsburgh.

Among his many grants and awards, Dr. Heeckt has received a German Research Council Fellowship, a Fellow Research Award of the American Gastroenterological Association, and was named an Adjunct Associate Professor of Orthopaedic Surgery, University of Pittsburgh. He served on the Supervisory Board of the Wittgensteiner Kliniken AG, Germany and on the European Scientific Advisory Board of New Drugs. More recently, Dr. Heeckt has been appointed to the Board of Trustees of the Ilse and Oskar Vidal Foundation in Hamburg, Germany, to the Advisory Board of the Institute of Healthcare Industries, Steinbeis University in Berlin, Germany, as Adjunct Professor of Surgery, University of Ulm, Germany and to the Board of Directors of InMotion Musculoskeletal Institute, Memphis.

Dr. Murray Height is Chief Technology Officer and Co-founder of HeiQ Materials. Originally from Australia, Murray studied chemical engineering at the University of Newcastle. In 1999 Murray traveled to the United States on a Fulbright Scholarship to pursue graduate studies at the Massachusetts Institute of Technology (MIT). Completing his PhD in 2003, Murray then traveled to Switzerland where he pursued nanomaterial research as part of a postdoctoral appointment at the Swiss Federal Institute of Technology (ETH Zurich). In early 2005 Murray founded HeiQ Materials with his friend and business partner Carlo Centonze. HeiQ offers a range of unique nanocomposite additives offering enhanced hygiene for plastic devices, textiles and surface coatings.

Dr. Ruediger Herrmann is a Partner in Mayer, Brown, Rowe & Maw's Frankfurt office and serves as the co-chair of Mayer, Brown, Rowe & Maw's Global Biotech Pharma Med Tec Practice Group. Rüdiger represents Biotech Pharma and Med Tec clients in Corporate Transactions, especially Private Equity and Venture Capital Transactions, as well as in Intellectual Property Transactions above all Technology Transfer Agreements, License Agreements, Collaboration and Co-Development Agreements.

Rüdiger received his law degree from the University in Mainz and was admitted to the bar in Wiesbaden in 1996. Rüdiger serves as the co-chair of the High-tech and Venture Capital Practice Group of Terralex, is member of the Biotechnologie Board of the Federal Association of Pharmaceutical Entrepreneurs in Germany and has been named as one of the expert attorneys in the field of Biotech in JUVE Handbook. Rüdiger speaks German (native), English and French fluently.

Giles Keating is a Managing Director of Credit Suisse in the Private Banking Division, based in Zurich. He is Head of Private Banking Research and through a common management structure also responsible for the research groups of Asset Management. Furthermore he is Chair of the Global Economics and Strategy Group of Credit Suisse.

Prior to joining Credit Suisse's Private Banking business in May 2004, Mr. Keating worked in the Investment Banking Division (formally Credit Suisse First Boston), where he held various posts, including Global Head of Fixed Income Research and Economics, Chief Economist, and Co-Head of the Pensions Advisory and Structuring Group.

Before joining Credit Suisse First Boston in 1986, Mr. Keating was a research fellow at the London Business School Centre for Economic Forecasting, where he built an econometric model of the U.K. financial system and was editor of "LBS Financial Outlook." He spent six years at the Confederation of British Industry, finishing as Head of the Economic Forecasting Department.

Mr. Keating received his B.A. in Philosophy, Politics and Economics from St. Catherine's College, Oxford University and his M.Sc. in Mathematical Economics and Econometrics from the London School of Economics. He has published widely in academic and general media on macro-economics, financial markets and public policy.

Dr. Christian Lach has been a member of the healthcare team of Bellevue Asset Management AG in Zurich which manages the portfolio of BB BIOTECH and BB MEDTECH since 2001. Before this position, he worked as an independent consultant in the area of innovation management and business process re-engineering.

Mr. Lach studied biochemistry at the University of Tübingen / Germany and at the ETH Zurich / Switzerland. After that he took his second degree in business administration followed by a doctorate at the University of St. Gallen. During his PhD studies he worked as a research assistant at the Institute for Technology Management (ITEM-HSG),

Speaker Biographies

where he led Benchmarking workshops as well as projects in the areas of Supply Chain Management and Innovations Management with various companies in the life science, machinery and consumer goods industry. Before that he worked during an internship with F. Hoffmann-La Roche AG in Basel within the business development department.

Dr. Olivier Litzka joined Edmond de Rothschild Investment Partners' (EdRIP) as a Partner in 2006. There, he invests in Biotechnology and Medtech companies mainly in Europe, partially in the US.

Before joining EdRIP, Olivier spent 6 years with 3i's life science venture capital practice, based first in Munich, later in Paris, serving on boards of several portfolio companies and investing internationally. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris.

Olivier holds a PhD in molecular microbiology from the "Institut für Mikrobiologie" at University of Munich and did his scientific research work over several years in Munich and Oxford.

Dr. Don Long is an Executive Editor for Atlanta, Georgia-based AHCmedia, the publisher of more than 60 newsletters dealing with medical and healthcare topics. Long writes for, edits and oversees a group of daily, weekly and monthly newsletters -- plus sourcebooks issued yearly -- focused primarily on medical technologies, including Medical Device Daily, Cardiovascular Device Update and Biomedical Business & Technology. The group's flagship publication is Medical Device Daily, which AHCmedia bills as the only five-days-a-week publication focused primarily on medical technology in the US and internationally.

Long initially earned a PhD in English literature and taught college English for several years before turning to journalism. While living in Chicago, he reported and edited for a wide range of daily and weekly publications and was the co-founder of and Editor of DuPage Magazine, a four-color monthly magazine covering news and features stories in the Chicagoland suburban area. After coming to Atlanta and helping to launch a business newspaper covering the northern Atlanta suburbs, he began reporting for Medical Device Weekly in May of 1997 and was instrumental in transforming it into a daily publication in 2001. He currently is the lead writer for the publication's weekly ezine, MDD Perspectives, which provides analysis and opinion on medical technologies and related healthcare issues in the US and internationally.

Michel E. Lussier, 50, Canadian, is Chairman of Cardio³ SA. He has lived in Europe since 1977. In March 2002 he founded MedPole S.A./N.V., a European Incubator for medical device start up companies located in Brussels.

Cardio³ SA, a start-up biotechnology company dedicated to cell transplant solutions for cardiovascular applications, is a creation of MedPole. Cardio³ was founded in November 2003 jointly with world renowned scientists and cardiologists, private and institutional investors.

Mr. Lussier started his career with Medtronic Corp., and during his 15 years with the company, he held number of positions varying from Clinical Engineering, Business Development, Sales and General Management both on French and European levels.

In 1994, Mr. Lussier founded and led the European subsidiary of InControl Corp., until its acquisition by Guidant in 1998. From 1998 until 2002 he then worked for Novoste Corp. where as Vice President, General Manager European Operations, he led the foundation of the company in Europe.

Mr. Lussier holds a diploma in Control Systems from ENSEEIHT, Toulouse, France, a BSEE and a MSBME from the University of Montreal. Mr. Lussier is also an INSEAD MBA graduate, 1985.

Dr. Darren Obrigkeit is the Licensing & Venturing Manager for DSM Biomedical, where he has been responsible for external partnerships, including development of an overall licensing & venturing strategy for the biomedical group. His venturing involvement spans all stages and aspects of the deal-making process from screening, defining the strategic rationale, and managing post-transaction developments at portfolio companies including Xylos, Oxford Performance Materials, and Micromuscle. In addition, Darren has developed licensing business practices to cover the unique needs of a company focused on the interface between polymeric materials, drug delivery, and advanced implantable devices.

Prior to joining DSM Biomedical in 2005, he was co-founder and Director of Engineering and Operations at Angstrom Medica, Inc., a synthetic bone substitute company. Darren gained a broad base of experience at Angstrom Medica ranging from writing the business plan, raising financing, building staff & infrastructure, and submitting the first approved FDA 510(k) for a nanomaterial-based device in 2004.

Darren's background is in chemical engineering (BSE, University of Michigan; MS, PhD, MIT) where he was funded by a National Science Foundation graduate fellowship. His industrial experience includes both start-up and Fortune 500 assignments: Merck, Dow Chemical, Ford Motor, and Aerodyne Research, among others.

Speaker Biographies

Dr. Alessandra Pavesio is a Director of the R&D Department at Fidia Advanced Biopolymers Srl. She holds a degree in pharmaceutical sciences, and has been in FAB (Fidia Advanced Biopolymers) since its inception.

As a director of FAB's research and development efforts, her focus is on the design, development and testing of novel biodegradable surgical specialties, and in the exploitation of tissue engineered solutions for application in wound care and skeletal tissue repair. As a founder of the company, she has co-authored more than 35 peer reviewed publications, has contributed to over 15 patented inventions and has managed the development of all of FAB's CE and FDA approved products. A pioneer in development of regenerative medicine therapeutic approaches, she coordinates a number of projects based on cell based therapies, amongst which STEPS, the largest ongoing EC funded program on Tissue Engineering. Since 2005, she has been nominated chairperson of the Regenerative Medicine section of the EC Technology Platform on Nanomedicine, with the objective of defining strategic research priorities for regenerative medicine projects to be funded in the VII Framework Program

Diane Romza-Kutz is a Member of the Firm, Health Care and Life Sciences Practice, Epstein Becker & Green P.C. in the firm's Chicago office, where she focuses on health care and pharmaceutical litigation. She also serves as Managing Partner for the Chicago office of the firm.

Ms. Romza-Kutz defends pharmaceutical, biotechnology and medical device companies in cases involving products liability issues, pricing issues, false claims act litigation, contract and fraud claims, consumer and third-party class actions, whistleblower claims and advertising, marketing disputes with regulatory bodies, off-label promotions and failure to adequately warn claims.

She also counsels pharmaceutical clients under government investigation as well as clients on national and international health care regulatory concerns, including FDA matters, clinical trials, labeling issues, marketing and advertising products, related fraud and abuse issues, anti-kickback issues, compliance with the Medicare Modernization Act, corporate and managed care contracting, alternative dispute resolution, in-and-out licensing strategies, and structuring joint ventures.

Ms. Romza-Kutz creates provider networks and related administrative and management agreements and handles civil and criminal health-care matters and managed-care contracting work for issuers, hospital networks, physicians and other providers. She litigates health care claims arising from regulatory, managed care or other related areas.

Ms. Romza-Kutz has tried numerous product-liability, class action and mass tort cases in both the federal and state courts. She has extensive transactional, regulatory, administrative and litigation experience.

Prior to joining EBG, Ms. Romza-Kutz was a Partner with Mayer, Brown Rowe & Maw LLP. Previous to that, she was a government attorney and prosecutor. Ms. Romza-Kutz was an Adjunct Professor for the Department of Criminal Justice at Loyola University where she also received her LLM in Health Law.

Eliane Schutte is senior partner of Signifix BV, a QA/RA consulting firm in life sciences. She has an academic degree in Health Sciences and Business Administration and is RAC certified. She provides strategic advise, support and interim management in regulatory affairs and quality systems for the life science industry. Her specific expertise is in complex medical devices or combinations of devices with human tissues (human cells), regenerative medicine and medical devices with active ingredients. She has more than 10 years experience in FDA (pre-)approval processes, CE marking, local authorizations as well as other international approvals (Asia, South America, Canada, Australia eg). She is actively participating in development of EU regulation regarding human tissue medical products and Advanced Therapy Medicinal Products.

Eliane is also Director International Regulatory Affairs for IsoTis Orthobiologics. IsoTis is a biomedical company developing a range of orthobiologic products like bone graft substitutes, based on human tissue. She manages regulatory affairs of IsoTis bone substitutes globally. She also has managed regenerative medicine products in the area of skin, cartilage and bone as well as medical devices. She developed successful strategies for various countries and maintained contacts with regulators such as FDA, notified bodies, EMEA, local regulatory authorities. Prior to joining IsoTis, she held a senior QA position at Medtronic.

Crispin Simon joined Biocompatibles in June 1998 as Group CEO. After graduating from Lincoln College, Oxford, Crispin joined NM Rothschild as an Investment Manager. He then moved to join McKinsey & Company as a consultant. Between 1987 and 1998 he gained general management experience at senior executive level with Rexam plc (then Bowater) and then with Smith & Nephew plc as Director of Business Development and ultimately as President of the Endoscopy Division, based in Boston, USA. Crispin is also a Non-Executive Director of Eumedic Limited.

Biocompatibles is a medical technology company focused on drug device Combination Products principally for use in oncology.

Speaker Biographies

The company has two businesses—Biocompatibles in Farnham (UK) and CellMed in Alzenau (Germany). Both divisions use bead technology to deliver a therapeutic agent – Farnham delivers established chemical formulations and CellMed deliver novel biological formulations, included stem cell-based therapies. Each business uses a proprietary polymer system for bead production and both businesses have first-generation bead products that do not contact any drug – Bead block and the Alginate Bead, respectively.

Anthony G. Viscogliosi is the founder, Chief Executive Officer & Chairman of Small Bone Innovations, Inc., New York. He has more than 20 years of experience in orthopedics. Prior to co-founding Viscogliosi Bros., LLC (VB) in 1999, he was an analyst at several brokerage and investment banking firms before rising to SVP & Director of Medical Technology at Stifel, Nicolaus & Co., Inc. In addition to founding SBI and VB he has helped develop and manage many firms in orthopedic devices such as Raymedica, Inc., Alliance Medical Corp., Spine Solutions, Inc., and MCRA, LLC. Mr. Viscogliosi holds a BS in Economics from the University of Michigan.

Dr. Maurice Wagner has been General Director of Eucomed since May 1, 2002. Eucomed is the Brussels based pan-European trade association that represents the medical technologies and devices industry. The mission of Eucomed is to contribute to improving patients and clinicians access to modern, innovative and reliable medical technology. Maurice Wagner joined Eucomed from the Worldwide and European Fragrance and Flavour Trade Associations for which he worked as Executive Director for 6 years. He started his business life with Hoffmann-La Roche, initially as a lawyer in Basel (Switzerland), where he was advising the group companies on all five continents, then in a marketing function in the UK, and finally as Manager EU-Affairs in Brussels, where he was in charge, in particular, of all contacts with the EU- Institutions and other stakeholders. Maurice Wagner studied law in Switzerland and completed his doctorate in the field of Intellectual Property.